Related Experiment Video
Updated: Nov 11, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Serotoninergic system targeting in multiple sclerosis: the prospective for pathogenetic therapy.
Mikhail Melnikov1, Anastasiya Sviridova2, Vladimir Rogovskii2
1Department of Neuroimmunology, Federal Center of Brain research and Neurotechnology of the Federal Medical-Biological Agency of Russia; Department of Neurology, Neurosurgery and Medical Genetics and Department of Molecular Pharmacology and Radiobiology, Pirogov Russian National Research Medical University, Moscow, Russia; Laboratory of Clinical Immunology, National Research Center Institute of Immunology of the Federal Medical-Biological Agency of Russia, Moscow, Russia.
Serotonin (5-hydroxytryptamine) influences central nervous system inflammation, particularly in multiple sclerosis (MS). This review explores serotonin
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Serotonin (5-hydroxytryptamine, 5-HT) is a key neurotransmitter regulating central nervous system (CNS) functions.
- Emerging evidence links 5-HT modulation of gut microbiota to CNS inflammatory diseases.
- 5-HT acts as a direct mediator in neuroimmune interactions.
Purpose of the Study:
- To review existing literature on the role of serotonin in regulating neuroinflammation in multiple sclerosis (MS).
- To discuss the impact of 5-HT and SSRIs on experimental autoimmune encephalomyelitis (EAE) and MS pathogenesis.
- To evaluate the therapeutic potential of serotoninergic drugs for MS.
Main Methods:
- Comprehensive literature review of studies investigating serotonin's role in neuroinflammation and MS.
- Analysis of data concerning the effects of 5-HT and SSRIs on EAE models.
- Evaluation of research on the pathogenetic mechanisms of MS and potential therapeutic targets.
Main Results:
- Serotonin plays a significant role in modulating neuroinflammation relevant to MS.
- Selective serotonin reuptake inhibitors (SSRIs) show potential influence on EAE and MS progression.
- Serotoninergic pathways represent a promising area for MS pathogenetic therapy.
Conclusions:
- Serotonin is implicated in the neuroinflammatory processes underlying multiple sclerosis.
- Targeting the serotoninergic system with drugs like SSRIs may offer a novel therapeutic strategy for MS.
- Further research is warranted to fully elucidate the therapeutic potential of serotoninergic agents in MS management.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Parkinson's Disease: Overview

